Please login to the form below

Not currently logged in
Email:
Password:

cardiomyopathy

This page shows the latest cardiomyopathy news and features for those working in and with pharma, biotech and healthcare.

Alnylam gets EU nod for Onpattro amid pricing backlash

Alnylam gets EU nod for Onpattro amid pricing backlash

for tafamidis as a treatment for cardiomyopathy associated with hATTR amyloidosis after reporting positive results in the phase III ATTR-ACT trial.

Latest news

More from news
Approximately 2 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    Onpattro looked to have the edge in terms of clinical data, but Pfizer has new data showing tafamidis is effective in treating patients with cardiomyopathy – the heart damage caused by the

  • Deal Watch February 2016 Deal Watch February 2016

    Annapurna brings a portfolio of four AAV-based gene therapy programmes at the preclinical stage for alpha-1 antitrypsin deficiency, hereditary angioedema, cardiomyopathy associated with Friedreich's ataxia and severe allergy.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    209. MyoKardia/ Sanofi. Licence and collaboration. 5. Three programmes for treatment of genetic forms of cardiomyopathy.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Myokardia will develop two HCM (hypertrophic cardiomyopathy) programmes where it retains US commercialisation rights and Sanofi has ex-US rights; and a third DCM (dilated cardiomyopathy) programme will be developed by

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    MyoKardia's genetically targeted approach and cutting-edge platform has the potential to fundamentally change the lives of patients with hypertrophic cardiomyopathy and dilated cardiomyopathy,” he said. “

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics